Followup data on improvement in objective findings (Model 1) and HQ scores (Model 2). Data are n (%) unless otherwise indicated.
| Variable | Univariate Model | Multivariable Logistic Regression Model | |||
|---|---|---|---|---|---|
| Model 1: Objective outcomes* | Improved < 5 (43 pts)* | Improved ≥ 5 (130 pts)* | p | p | OR (95% CI) |
| Age at onset, yrs, mean ± SD | 9.25 ± 4.02 | 7.34 ± 4.64 | 0.018 | 0.04 | 0.91 (0.84–0.99) |
| Ethnicity: not Hispanic or Latino | 41 (95.3) | 114 (87.7) | NS | ||
| Race: white | 39 (90.7) | 119 (75.3) | NS | ||
| Sex, female | 17 (39.5) | 93 (71.5) | < 0.0001 | 0.001 | 3.43 (1.64–7.17) |
| DMARD | 29 (69.0) | 77 (59.7) | NS | ||
| bDMARD | 25 (59.5) | 65 (50.0) | NS | ||
| GC | 8 (19.0) | 23 (17.7) | NS | ||
| Daily NSAID | 17 (40.5) | 43 (33.3) | NS | ||
| Model 2: HQ outcomes** | Not Improved in All (163 pts)** | Improved All (11 pts)** | p | p | OR (95% CI) |
|---|---|---|---|---|---|
| Age at onset | 7.98 ± 4.62 | 7.12 ± 4.31 | NS | ||
| Ethnicity: not Hispanic or Latino | 147 (90.2) | 11 (100) | NS | ||
| Race: white | 152 (93.3) | 10 (90.9) | NS | ||
| Sex, male | 59 (36.2) | 6 (54.5) | NS | ||
| Psoriasis | 111 (69.4) | 8 (72.7) | NS | ||
| Nail pitting | 53 (33.8) | 7 (63.6) | 0.056 | 0.13 | 2.75 (0.74–10.18) |
| Dactylitis | 43 (27.7) | 3 (27.3) | NS | ||
| Enthesitis | 42 (27.1) | 7 (63.6) | 0.016 | 0.03 | 4.14 (1.12–15.25) |
| Sacroiliitis | 26 (16.7) | 3 (27.3) | NS | ||
| Oligoarthritis | 57 (35) | 4 (40.0) | NS | ||
| Polyarthritis | 106 (65) | 6 (60) | NS | ||
| DMARD | 102 (63.0) | 6 (54.5) | NS | ||
| bDMARD | 82 (50.3) | 7 (63.6) | NS | ||
| GC | 29 (17.8) | 3 (27.3) | NS | ||
| Daily NSAID | 60 (37.0) | 3 (27.3) | NS |
↵Model 1: Objective outcomes*: psoriasis, nail pitting, dactylitis, arthritis, enthesitis, and sacroiliitis. Improved in < 5 from the following variables: psoriasis, nail pitting, dactylitis, arthritis, enthesitis, and sacroiliitis. Improved in ≥ 5 from the following variables: psoriasis, nail pitting, dactylitis, arthritis, enthesitis and sacroiliitis.
↵Model 2: Health questionnnaire (HQ) outcomes**: 4 HQ (PAINSC, HRQOL, GLASWBSC, and PGA). Improved in < 4 HQ (PAINSC, HRQOL, GLASWBSC, and PGA). Improved in all 4 HQ (PAINSC, HRQOL, GLASWBSC, and PGA). NS: nonsignificant; PGA: physician global assessment; DMARD: disease-modifying antirheumatic drug; GC: glucocorticosteroids; NSAID: nonsteroidal antiinflammatory drugs; bDMARD: biologic DMARD; HRQOL: health-related quality of life; PAINSC: parent/subject pain scale; GLASWBSC: parent/subject overall well-being.